Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Family Medicine
Alzheimer's Disease Clinical Trials
A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Arizona
Sun City : Banner Sun Health Research Institute
A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety,and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patients with Alzheimer’s disease.
Sun City : Banner Sun Health Research Institute
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Sun City : Banner Sun Health Research Institute
A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline
Sun City : Banner Sun Health Research Institute
ADvance: A 12-month double-blind, randomized, controlled feasibility study to evaluate the safety, efficacy and tolerability of deep brain stimulation of the fornix (DBS-f) in patients with mild probable Alzheimer’s disease
Sun City : Banner Sun Health Research Institute
Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)
Sun City : Banner Sun Health Research Institute
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease
View More »
Goodyear : Call for Information (Investigational Site 0002)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Phoenix : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Phoenix : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Phoenix :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Phoenix : Barrow Neurological Institute
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Phoenix :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Scottsdale : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Sun City : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Sun City : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sun City :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Sun City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Tucson : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Arkansas
Fayetteville : Call for Information (Investigational Site 0047)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
California
Encino : Pharmacology Research Institute, Encino
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease
Encino : Pharmacology Research Institute, Encino
Study of an investigational medication for the treatment of Alzheimer's Disease
Glendale : California Clinical Trials Medical Group, Inc.
Alzheimer's Disease Study
Los Alamitos : Pharmacology Research Institute, Los Alamitos
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease
Los Alamitos : Pharmacology Research Institute, Los Alamitos
Study of an investigational medication for the treatment of Alzheimer's Disease
Newport Beach : Pharmacology Research Institute, Newport Beach
Study of an investigational medication for mild to moderate Alzheimer's Disease
Newport Beach : Pharmacology Research Institute, Newport Beach
Study of an investigational medication for the treatment of Alzheimer's Disease
Sacramento : Sutter Institute for Medical Research (SIMR)
Mild Cognitive Impairment
Santa Ana : Apex Research Institute
Alzheimers? Be a Part of Research.
Santa Rosa : Radiant Research - Santa Rosa
Alzheimer's Disease Research Study
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Clinical research study of an investigational medication vs. placebo for agitation
in persons with Alzheimer’s disease.
Sherman Oaks : Schuster Medical Research Institute
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease.
View More »
Aliso Viejo : Avanir Pharmaceuticals
PRISM Registry: Pseudobulbar Affect Registry Series
Costa Mesa : ATP Clinical Research, Inc. Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Costa Mesa : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Encino : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Escondido : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Escondido :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Fountain Valley : Call for Information (Investigational Site 0050)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Fountain Valley :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Fresno : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Fresno :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Fullerton : Call for Information (Investigational Site 0079)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Garden Grove : Collaborative Neuroscience Network, Inc. Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Glendale : California Clinical Trials Medical Group, Inc.
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Glendale : Glendale Adventist Medical Center
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
Laguna Hills : Senior Clinical Trials, Inc. Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Laguna Hills :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Lomita :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Long Beach :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Long Beach : Collaborative Neuroscience Network Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Long Beach : Call for Information (Investigational Site 0053)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Long Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Long Beach :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Long Beach : Site Reference ID/Investigator# 84185 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Los Alamitos : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Los Angeles :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Sacramento : Call for Information (Investigational Site 0007)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
San Diego : Pacific Research Network Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
San Diego :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Diego :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
San Francisco :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Francisco : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
San Francisco :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
San Francisco : Site Reference ID/Investigator# 84183 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
San Francisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
San Francisco : Ucsf Memory And Aging Center Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Santa Ana : Research Across America Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Santa Ana : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Santa Monica : Neurological Research Institute Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Santa Monica :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Sherman Oaks :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Sherman Oaks :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Valencia : Sanguine Biosciences
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
Colorado
Boulder : Alpine Clinical Research Center
New Investigational Medication for Autism, Asperger's Disorder, or Pervasive Developmental Disorder in Pediatric Patients (PDD-NOS)
Boulder : Alpine Clinical Research Center
New Investigational Medication for Mild Alzheimer's Disease
Denver : Radiant Research - Denver
Memory Loss Research Study
View More »
Boulder : Alpine Clinical Research Center Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Boulder : Alpine Clinical Research Center, Inc. Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Connecticut
Fairfield : Associated Neurologists Of Southern Connecticut, P.C. Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Hamden : Site Reference ID/Investigator# 84187 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Hamden : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
New Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Norwalk : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
View More »
Norwich : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Waterbury : Chase Medical Research, LLC Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
District of Columbia
Washington : Call for Information (Investigational Site 0077)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Florida
Hallandale Bch : MD Clinical Updated
Are you more forgetful lately?
Hallandale Beach : MD Clinical
Is your memory loss just a sign of age, or something else?
Miami : Research Site
Alzheimer’s Research Study ITN# 12038
Miami : Research Site
Alzheimer's Disease ITN# 12129
Miami : Research Site
Alzheimer's Disease ITN# 12160
Ocala : Renstar Medical Research
Alzheimer's Disease
St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL
Alzheimer’s Disease ITN# 12032
St. Petersburg : Meridien Research
Alzheimer's Disease
Tampa : Axiom Clinical Research of Florida
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
Tampa : Axiom Clinical Research of Florida
A Phase Ii, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Ro4602522 Added To The Background Therapy Of The Acetylcholinesterase Inhibitors Donepezil Or Rivastigmine In Patients With Moderate Severity Alzheimer's Disease
Tampa : Axiom Clinical Research of Florida
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Tampa : Axiom Clinical Research of Florida
A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel Group Study Of The Safety And Efficacy Of PF-05212377 (SAM-760) In Subjects With Mild-To-Moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil
Tampa : Axiom Clinical Research of Florida
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
View More »
Atlantis : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Brooksville : Meridian Research Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Brooksville :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Brooksville : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Clearwater : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Deerfield Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Deerfield Beach :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Deerfield Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Delray Beach : Brain Matters Research Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Delray Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 56503
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Delray Beach : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Delray Beach :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 84178 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Delray Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Delray Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 73493
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Fort Lauderdale : Call for Information (Investigational Site 0008)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Fort Myers : Neuropsychiatric Research Center of Southwest Florida Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Fort Myers : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Hallandale Beach :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Hallandale Beach : MD Clinical Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Hallandale Beach : Call for Information (Investigational Site 0059)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Hallandale Beach : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Hallandale Beach :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Hallandale Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Hollywood : Call for Information (Investigational Site 0063)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Jacksonville :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Lake Worth : Alzheimer's Research and Treatment Center Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Lake Worth : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Miami : Miami Jewish Health Systems Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Miami : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Miami :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Miami :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Miami Beach : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Oakland Park : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Ocala : Call for Information (Investigational Site 0058)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Orlando :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Orlando : Compass Research, LLC Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Orlando : Call for Information (Investigational Site 0018)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Orlando : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Orlando : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Orlando : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Orlando :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Orlando : Site Reference ID/Investigator# 84180 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Orlando : Compass Research, Llc Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Ormond Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Palm Beach Gardens : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Palm Beach Gardens : Palm Beach Neurological Center Advanced Research Consultants Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Port Charlotte : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sarasota : The Roskamp Institute Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Sarasota : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sunrise : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sunrise :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Tampa :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Tampa : Axiom Clinical Research of Florida Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Tampa :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Tampa : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Tampa : Site Reference ID/Investigator# 84188 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Tampa : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
West Palm Beach : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
West Palm Beach :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
West Palm Beach : Site Reference ID/Investigator# 56514
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
West Palm Beach : Site Reference ID/Investigator# 84186 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
West Palm Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
West Palm Beach : Site Reference ID/Investigator# 73496
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Weston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Georgia
Atlanta : NeuroTrials Research
New Alzheimer’s Disease Research
View More »
Atlanta :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Atlanta : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Decatur :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Savannah : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Illinois
Elk Grove Village : Alexian Brothers Hospital Network
A multinational, multicenter, randomized, double-blind, parallel-group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy
Elk Grove Village : Alexian Brothers Hospital Network
A phase 2 multicenter, double-blind, placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's Disease on stable Donepezil therapy.
Elk Grove Village : Alexian Brothers Hospital Network
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Subjects with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carriers
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Diseases
View More »
Chicago : Call for Information (Investigational Site 0064)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Chicago : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Elk Grove Village : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Elk Grove Village :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Elk Grove Village : Site Reference ID/Investigator# 62611
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Elk Grove Village :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Elk Grove Village : Site Reference ID/Investigator# 84182 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Elk Grove Village : Alexian Brothers Neurosciences Institute Clinical Research Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Elk Grove Village : Site Reference ID/Investigator# 73495
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Springfield : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Kentucky
Louisiana
Lake Charles : Lake Charles Clinical Trials
Study of PF-05212377 in Participants with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil
Lake Charles : Lake Charles Clinical Trials
Studying the Effects of Daily Administration of AC-1204 versus Placebo in People with Mild to Moderate Alzheimer's Disease (AD).
View More »
Baton Rouge : Call for Information (Investigational Site 0043)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Lake Charles : Lake Charles Clinical Trials Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Shreveport : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Maine
Bangor : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Maryland
Baltimore : Call for Information (Investigational Site 0040)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Massachusetts
Boston : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Boston : Beth Israel Deaconess Medical Center
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
Boston : Brigham And Women'S Hospital Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Chestnut Hill : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Haverhill :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Plymouth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Quincy : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Quincy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Winchester : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Michigan
Kalamazoo : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Lansing : Michigan State University Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Mississippi
Hattiesburg : Hattiesburg Clinic Neurological Research Center
Mayflower: A phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to investigate the efficacy and safety of RO4602522 added to the background therapy of the acetylcholinesterase inhibitors Donepezil or Rivastigmine in patients with moderate severity Alzheimer’s Disease
View More »
Flowood : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Olive Branch :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Missouri
Kansas City : Call for Information (Investigational Site 0025)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
St. Louis : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Nevada
Las Vegas : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Las Vegas :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
New Jersey
Stratford : University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine
Alzheimer's disease study for mild to moderate AD.
View More »
Eatontown : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Eatontown :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Manchester : Alzheimer's Research Corporation Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Monroe Township :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Monroe Township : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Princeton : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Summit : The Cognitive Research Center of New Jersey Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Summit :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Summit :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Toms River : Memory Enhancement Center of NJ Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Toms River : Call for Information (Investigational Site 0054)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Toms River :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Toms River : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Toms River :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
New York
New Hyde Park : Parker Jewish Institute
This study will investigate the safety and efficacy of immune globulin intravenous, for the treatment of mild to moderate Alzheimer's Disease.
New York : The Rockefeller University Hospital
Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer’s Disease
New York : Biomedical Research Alliance of New York
People with Alzheimer’s disease are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.
View More »
Albany :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Brooklyn : SPRI Clinical Trials, LLC Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Brooklyn :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Manhasset : Call for Information (Investigational Site 1061)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Orangeburg :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Patchogue : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Rochester : Call for Information (Investigational Site 0089)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Rochester : Call for Information (Investigational Site 0039)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Rochester : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Rochester :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Staten Island : Site Reference ID/Investigator# 56506
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Staten Island :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Staten Island : Site Reference ID/Investigator# 84181 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Staten Island : Site Reference ID/Investigator# 73494
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
North Carolina
Charlotte : PMG Research of Charlotte
Does your loved one with Alzheimer's Disease display aggression or agitation?
Greensboro : Guilford Neurologic Associates
Impact of Florbetapir F 18 PET on the Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
Raleigh : Multi-Specialty Research Associates of NC
Is Alzheimer’s Disease affecting your loved one?
Wilmington : PMG Research of Wilmington Updated
Does your loved one with Alzheimer’s Disease display aggression or agitation?
Winston-Salem : PMG Research of Winston-Salem
Do you care for someone afflicted with Alzheimer's Disease?
View More »
Charlotte : Call for Information (Investigational Site 0013)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Charlotte : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Durham : Duke Health Center at Morreene Road
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
Durham : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Durham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Greensboro : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Raleigh : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Wilmington : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Winston-Salem : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Ohio
Beachwood : Call for Information (Investigational Site 0033)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Beachwood : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Canton : Neuro-Behavioral Clinical Research, Inc. Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Canton : Call for Information (Investigational Site 0010)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Canton :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
View More »
Centerville :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Cincinnati : Community Research Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Cleveland :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Columbus :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Columbus : The Ohio State University Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Lakewood :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Toledo : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Oklahoma
Oklahoma City : Call for Information (Investigational Site 0027)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Oklahoma City : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Oklahoma City :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Tulsa : Call for Information (Investigational Site 0055)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Oregon
Pennsylvania
Abington : Call for Information (Investigational Site 0081)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Abington : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Jenkintown : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Jenkintown : Site Reference ID/Investigator# 82994
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Jenkintown :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Jenkintown : The Clinical Trial Center, Llc Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Norristown : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Philadelphia : Penn Memory Center Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Philadelphia : Hospital Of The University Of Pennsylvania Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Pittsburgh : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Rhode Island
East Providence :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
East Providence : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Providence : Call for Information (Investigational Site 0060)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Providence : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
South Carolina
Greer : Radiant Research - Greer
Clinical Research Study for Alzheimer's Disease
View More »
North Charleston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Port Royal : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Tennessee
Nashville : Clinical Research Associates, Inc.
Alzheimer's Disease Research Study
View More »
Cordova : Neurology Clinic, P.C. Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Cordova : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Kingsport : Call for Information (Investigational Site 0049)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Memphis : Clinical Neuroscience Solutions, Inc Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Memphis :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Nashville : Call for Information (Investigational Site 0045)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Texas
Dallas : Texas Neurology, PA
Alzheimer's Research Study
Dallas : Texas Neurology, PA
Mild Cognitive Impairment
View More »
Austin : Senior Adults Specialty Research, Inc Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Austin : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Dallas : Call for Information (Investigational Site 0076)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Dallas : Call for Information (Investigational Site 0074)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
DeSoto : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Houston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Antonio :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Antonio : CEDRA Clinical Research, LLC
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
Wichita Falls : Site Reference ID/Investigator# 77636
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Utah
Salt Lake City : Lifetree Clinical Research
Alzheimer's Research Study
Salt Lake City : CRI Lifetree
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease
Salt Lake City : Lifetree Clinical Research
Patients are defined as otherwise healthy males or females as determined by medical history, physical examination and a diagnosis of AD and must be at least 45 years of age.
Salt Lake City : Lifetree Clinical Research
Patients who have a diagnosis of probable AD and experience agitation.
Salt Lake City : Lifetree Clinical Research
Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
Salt Lake City : Lifetree Clinical Research
Subjects with Mild Alzheimer's Disease
Salt Lake City : CRI Lifetree
The objectives of the study are to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with AD.
Salt Lake City : CRI Lifetree
To assess the safety, tolerability, and the effects of of BMS-241027 on CSF Tau Nterminal domain fragment in subjects with mild Alzheimer’s Disease (AD).
Salt Lake City : CRI Lifetree
To evaluate the effect of gantenerumab vs. placebo on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability
View More »
Murray : Call for Information (Investigational Site 0004)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Salt Lake City : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Salt Lake City :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Salt Lake City : Lifetree Clinical Research Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Vermont
Bennington : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Bennington :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Bennington : Site Reference ID/Investigator# 56504
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Bennington : Site Reference ID/Investigator# 84179 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Burlington : Fletcher Allen Health Care-Clinical Neuroscience Research Unit
Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
Virginia
Richmond : National Clinical Research - Richmond, Inc. Updated
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Richmond : Call for Information (Investigational Site 0062)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Richmond : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Washington
Bellevue : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Richland : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Wisconsin
Milwaukee : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Waukesha : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Australia
Randwick : GSK Investigational Site
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
Canada
Gatineau : Site Reference ID/Investigator# 84173 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Greenfield Park : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Kelowna : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Kirkland : Merck Frosst Canada
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
London : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
View More »
Peterborough : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Peterborough : Site Reference ID/Investigator# 84177 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Toronto : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Toronto : Site Reference ID/Investigator# 84175 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Toronto : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Verdun : Site Reference ID/Investigator# 84176 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
China
Baoding : Hebei mental health center
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Beijing : Novartis Investigative Site
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Beijing : Peking University Institute of Mental Health
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Beijing : Beijing HuiLongGuan Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Beijing : Beijing Shijitan Hospital, EMU
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
View More »
Changchun : The first Affiliated Hospital of Jilin University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Guangzhou : Guangzhou Brain Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Guilin : Affiliated Hospital of Guilin Medical University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Hangzhou : The First Affiliated Hospital of Medical School of Zhejiang University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Kunming : First Affiliated Hospital of Kunming Medical University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Nanjing : Jiangsu Province Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Mental Health Center
Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai First People's Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Changzheng Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Tenth People's hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Finland
Turku :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
France
Aix En Provence : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Caen : CHU de la Côte de Nacre
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Cahors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Castres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Clermont-Ferrand : CHU Clermont-Ferrand
Alzheimer and Sleep
View More »
Dijon Cedex : Site Reference ID/Investigator# 84376 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Foix Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Lavaur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Léon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Lille Cedex : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Limoges : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Limoges Cedex : Site Reference ID/Investigator# 84373 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Marseille : Hôpital Sainte-Marguerite
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Montauban Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Montpellier cedex : CHU Gui de Chauliac
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Nantes : Hôpital Guillaume et René Laennec
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Nice : Hôpital de l'Archet
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Nice : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Paris : MSD France
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Paris : Pitié-Salpêtrière Hospital - Fédération de Neurologie
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Pitié-Salpêtrière Hospital
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Site Reference ID/Investigator# 84377 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Paris : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Paris Cedex 10 : Site Reference ID/Investigator# 84374 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Pierre Bénite : Investigational Site Number 250001 Updated
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Rennes : Hôpital Pontchaillou
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Rouen : Hôpital Charles Nicolle
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Saint-Brieuc : Centre Hospitalier
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Saint-Etienne : Hôpital Bellevue
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Strasbourg : Hôpital Civil
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Toulouse : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Toulouse Cedex 09 : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Vic-En-Bigorre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Germany
Berlin : Site Reference ID/Investigator# 84382 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Berlin : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Freiburg : Site Reference ID/Investigator# 84380 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Heidelberg : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Huettenberg : Site Reference ID/Investigator# 84383 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
View More »
Mittweida : Site Reference ID/Investigator# 84379 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Munich : Site Reference ID/Investigator# 84381 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Schwerin : Site Reference ID/Investigator# 84378 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Greece
Athens : Site Reference ID/Investigator# 84388 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Athens : Site Reference ID/Investigator# 84385 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Haidari, Athens : Site Reference ID/Investigator# 84386 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Thessaloniki : Site Reference ID/Investigator# 84390 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Israel
Tel Aviv : Merchav Clinics
Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease
Tel Aviv : Tel Aviv Sourasky Medical Center, Neurology Department
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
Italy
Bergamo : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Genoa : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Milan : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Pisa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Rome : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
View More »
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Japan
Anjo-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Azumino-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Chiyoda-Ku, Tokyo : MSD K.K.
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Fukui-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Fukuoka-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
View More »
Fukuoka-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Hachioji-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kamakura-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kamakura-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kansai : Kansai region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Kanto : Kanto region,
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Kanto :
Safety and Efficacy of MT-4666
Kasukabe-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kawasaki-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kawasaki-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kita-gun : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kitamorokata-gun : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Koshi-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Koshi-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Koshigaya-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kumamoto City : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kyoto : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kyoto-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kyoto-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kyushu : Kyushu region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Miyoshi-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Miyoshi-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Musashino-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Nagoya : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Ohtake : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Sagamihara : Pfizer Investigational Site Updated
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Sapporo-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Setagaya-ku : Pfizer Investigational Site Updated
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Suita-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Toakai : Tokai region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Tohoku : Tohoku region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Toon-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Yokohama : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Korea, Republic of
Daejeon : Chungnam national university hospital, Daejeon Geriatric Medical Center
Effect of NeuroAD on Alzheimer Patients
Goyang : National Health Insurance Corporation Ilsan Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Incheon : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Seoul : SKChemicals invetigational site
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
Seoul : Samsung Medical Center
Clinical Trial of Donepezil Between the Naive Group and the Switching Group
View More »
Seoul : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Seoul : Kyung Hee University Oriental Medicine Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Seoul : The Catholic University of Korea, Seoul St. Mary's Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Seoul City : Samsung Medical Center
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
Suwon : The Catholic University of Korea, St. Vincent's Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Netherlands
New Zealand
Wellington : Merck Sharp & Dohme (New Zealand) Ltd.,
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Poland
Gdynia : Site Reference ID/Investigator# 62565
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Gdynia : Site Reference ID/Investigator# 73513
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Poznan : Site Reference ID/Investigator# 62563
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Poznan : Site Reference ID/Investigator# 73514
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Szczecin : Site Reference ID/Investigator# 62562
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Szczecin : Site Reference ID/Investigator# 73515
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Russian Federation
Kazan : Site Reference ID/Investigator# 60955
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kazan : Site Reference ID/Investigator# 60945
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kazan : Site Reference ID/Investigator# 73516
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Kazan : Site Reference ID/Investigator# 73525
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Kirov : Site Reference ID/Investigator# 60954
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Kirov : Site Reference ID/Investigator# 73523
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Moscow : Site Reference ID/Investigator# 60959
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Moscow : Site Reference ID/Investigator# 60951
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Moscow : Site Reference ID/Investigator# 73521
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Novosibirsk : Site Reference ID/Investigator# 60946
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Novosibirsk : Site Reference ID/Investigator# 73517
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Saratov : Site Reference ID/Investigator# 60950
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Saratov : Site Reference ID/Investigator# 73520
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
St. Petersburg : Site Reference ID/Investigator# 60947
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60949
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60952
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60958
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 84615
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
St. Petersburg : Site Reference ID/Investigator# 73518
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
St. Petersburg : Site Reference ID/Investigator# 73522
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
St. Petersburg : Site Reference ID/Investigator# 73524
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
South Africa
Belville : Site Reference ID/Investigator# 60911
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Belville : Site Reference ID/Investigator# 84395 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Belville : Site Reference ID/Investigator# 73507
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Cape Town : Site Reference ID/Investigator# 76073
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Cape Town : Site Reference ID/Investigator# 84391 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
View More »
George : Site Reference ID/Investigator# 60912
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
George : Site Reference ID/Investigator# 84393 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
George : Site Reference ID/Investigator# 73505
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Johannesburg : Site Reference ID/Investigator# 60910
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Johannesburg : Site Reference ID/Investigator# 84394 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Johannesburg : Site Reference ID/Investigator# 73506
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Rosebank : Site Reference ID/Investigator# 84392 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Spain
Sweden
Stockholm : Local Institution Updated
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Ukraine
Donetsk : Site Reference ID/Investigator# 60909
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Donetsk : Site Reference ID/Investigator# 73533
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Kiev : Site Reference ID/Investigator# 60906
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kiev : Site Reference ID/Investigator# 73534
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Poltava : Site Reference ID/Investigator# 60905
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Poltava : Site Reference ID/Investigator# 73535
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
United Kingdom
Bath : Site Reference ID/Investigator# 60960
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Bath : Site Reference ID/Investigator# 84398 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Bath : Site Reference ID/Investigator# 73502
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Blackburn : Site Reference ID/Investigator# 60963
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Blackburn : Site Reference ID/Investigator# 73503
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
View More »
Blackpool :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Bradford :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Cambridge : GSK Investigational Site
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
Cannock :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Glasgow : Site Reference ID/Investigator# 60962
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Glasgow : Site Reference ID/Investigator# 84397 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Glasgow : Site Reference ID/Investigator# 73501
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Hoddesdon : Merck Sharp & Dohme Ltd.
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
London : Site Reference ID/Investigator# 60961
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
London : Site Reference ID/Investigator# 84400 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
London : Site Reference ID/Investigator# 73504
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Manchester :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Manchester : Site Reference ID/Investigator# 84399 Updated
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Southampton : Memory Assessment and Research Centre, Moorgreen Hospital
Safety and Tolerability of Etanercept in Alzheimer's Disease
